Cover Image
市場調查報告書

ViroStatics, srl - 產品平台分析

ViroStatics, srl - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 219751
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
ViroStatics, srl - 產品平台分析 ViroStatics, srl - Product Pipeline Review - 2015
出版日期: 2015年07月31日 內容資訊: 英文 22 Pages
簡介

ViroStatics, srl是為了減少患者的病毒負擔,修復免疫功能障礙以治療病毒感染和慢性發炎疾病而進行研究開發的生物製藥公司。該公司所開發的激酶細胞,CDK9被用於治療感染疾病和癌症,發炎性疾病上。

本報告提供ViroStatics, srl的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

ViroStatics, srl的基本資料

ViroStatics, srl 概要

  • 主要資訊
  • 企業資料

ViroStatics, srl:研究開發 概要

  • 主要的治療範圍

ViroStatics, srl:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

ViroStatics, srl:開發中產品概況

  • 初期階段產品開發中產品
    • 藥物研發中的產品/聯合治療模式

ViroStatics, srls:藥物簡介

  • Small Molecule to Inhibit CDK9 for EBV and HSV Infections
  • Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts
  • Small Molecule to Inhibit CDK9 for Oncology
  • Small Molecule to Inhibit CDK9 for Rheumatoid Arthritis
  • VS-1002
  • VS-1003
  • VS-1004
  • VS-1005
  • VS-1006
  • VS-1007
  • VS-1008
  • VS-1010
  • VS-1011
  • VS-1013
  • VS-1014
  • VS-1016
  • VS-1017
  • VS-1018
  • VS-1019
  • VS-1020
  • VS-1021
  • VS-1022
  • VS-1023
  • VS-1024
  • VS-1025
  • VS-1026
  • VS-1027
  • VS-1028
  • VS-1032
  • VS-1033
  • VS-1034
  • VS-1035
  • VS-1036
  • VS-lOI l
  • VSl-001
  • VSl-010

ViroStatics, srl:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

ViroStatics, srl:暫停中的計劃

ViroStatics, srl:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07254CDB

Summary

Global Markets Direct's, 'ViroStatics, srl - Product Pipeline Review - 2015', provides an overview of the ViroStatics, srl's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ViroStatics, srl's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ViroStatics, srl including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ViroStatics, srl's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ViroStatics, srl's pipeline products

Reasons to buy

  • Evaluate ViroStatics, srl's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ViroStatics, srl in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ViroStatics, srl's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ViroStatics, srl and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ViroStatics, srl
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ViroStatics, srl and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ViroStatics, srl Snapshot
    • ViroStatics, srl Overview
    • Key Information
    • Key Facts
  • ViroStatics, srl - Research and Development Overview
    • Key Therapeutic Areas
  • ViroStatics, srl - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • ViroStatics, srl - Pipeline Products Glance
    • ViroStatics, srl - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ViroStatics, srl - Drug Profiles
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV and HSV Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ViroStatics, srl - Pipeline Analysis
  • ViroStatics, srl - Pipeline Products by Target
  • ViroStatics, srl - Pipeline Products by Molecule Type
  • ViroStatics, srl - Pipeline Products by Mechanism of Action
  • ViroStatics, srl - Dormant Projects
  • ViroStatics, srl - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ViroStatics, srl, Key Information
  • ViroStatics, srl, Key Facts
  • ViroStatics, srl - Pipeline by Indication, 2015
  • ViroStatics, srl - Pipeline by Stage of Development, 2015
  • ViroStatics, srl - Monotherapy Products in Pipeline, 2015
  • ViroStatics, srl - Partnered Products in Pipeline, 2015
  • ViroStatics, srl - Partnered Products/ Combination Treatment Modalities, 2015
  • ViroStatics, srl - Preclinical, 2015
  • ViroStatics, srl - Discovery, 2015
  • ViroStatics, srl - Pipeline by Target, 2015
  • ViroStatics, srl - Pipeline by Molecule Type, 2015
  • ViroStatics, srl - Pipeline Products by Mechanism of Action, 2015
  • ViroStatics, srl - Dormant Developmental Projects,2015

List of Figures

  • ViroStatics, srl - Pipeline by Top 10 Indication, 2015
  • ViroStatics, srl - Pipeline by Stage of Development, 2015
  • ViroStatics, srl - Monotherapy Products in Pipeline, 2015
  • ViroStatics, srl - Partnered Products in Pipeline, 2015
  • ViroStatics, srl - Pipeline by Top 10 Target, 2015
  • ViroStatics, srl - Pipeline by Top 10 Molecule Type, 2015
  • ViroStatics, srl - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top